Dyadic International and Israel Institute for Biological Research, IIBR, announced it has advanced its collaboration with the Israel Institute for Biological Research and its commercial arm Life Science Research Israel, LSRI, to target emerging disease solutions. This partnership aims to leverage Dyadic’s expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR. The IIBR will enhance Dyadic’s C1 cell lines using proprietary gene sequences to improve biomanufacturing of recombinant vaccines and neutralizing agents, including targeted antigens and monoclonal antibodies. The joint effort is focused on addressing emerging diseases through global commercial out-licensing initiatives to increase access and affordability of vaccines and antibodies to patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DYAI:
- Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats andĀ Emerging Disease Solutions
- Dyadic, Cygnus announce partnership to provide C1 HCP ELISA Assay
- Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
- Dyadic International announces research, development collab agreement
- Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company